ENXTPA:NEX
ENXTPA:NEXElectrical

Does Nexans Still Offer Value After Strong Multi Year Share Price Gains?

If you are wondering whether Nexans at €124.40 is still a smart buy after its strong run, or if most of the upside is already priced in, this piece will walk you through the key valuation angles to help you decide. The stock has dipped 1.0% over the last week, but that comes after a solid 4.0% gain over the past month, a 19.3% rise year to date and a 22.8% jump over the last year, building on a 55.7% 3-year and 129.8% 5-year performance. Those moves have been underpinned by Nexans’ strategic...
ENXTPA:SU
ENXTPA:SUElectrical

Schneider Electric (ENXTPA:SU): Revisiting Valuation After Recent Gains and Longer-Term Shareholder Returns

Schneider Electric (ENXTPA:SU) has been quietly grinding higher over the past month, adding about 6% even after a softer past week. That mix of short term noise and steady gains makes the current setup interesting. See our latest analysis for Schneider Electric. That recent 6.4% 1 month share price return sits against a slightly negative year to date move, while a modest 1 year total shareholder return of 0.7% caps a far stronger 3 year total shareholder return above 90%. This suggests...
ENXTPA:ALO
ENXTPA:ALOMachinery

Assessing Alstom (ENXTPA:ALO)’s Valuation After Its Recent Share Price Momentum

Alstom (ENXTPA:ALO) has quietly outperformed the broader market over the past quarter, with the stock up roughly 11% in the past month and 15% over the past 3 months. See our latest analysis for Alstom. Zooming out, that 10.59% 1 month share price return builds on a solid year to date gain. A 1 year total shareholder return of 13.83% suggests sentiment is steadily improving despite a still weak 5 year total shareholder return. If Alstom’s recent momentum has caught your attention, it could be...
ENXTPA:SAF
ENXTPA:SAFAerospace & Defense

How Safran’s Trading Volume Surge and Aerospace Rebound Exposure Will Impact Safran (ENXTPA:SAF) Investors

Safran recently saw a 300%+ jump in trading volume as investors reacted to its positioning in a recovering aerospace and defense market and looked ahead to its February 2026 earnings announcement. This surge in activity highlights how expectations around Safran’s focus on aircraft interiors, avionics and propulsion systems are shaping investor interest in the sector. We’ll now examine how this renewed trading interest, tied to Safran’s aerospace rebound exposure, interacts with and...
ENXTPA:BNP
ENXTPA:BNPBanks

BNP Paribas (ENXTPA:BNP): Revisiting Valuation After a Strong Year-to-Date Share Price Rally

BNP Paribas (ENXTPA:BNP) has been quietly grinding higher this year, and with the stock up about 35 % year-to-date, it is a good moment to revisit what is actually driving that strength. See our latest analysis for BNP Paribas. That move has not come out of nowhere, with a 13.9% 1 month share price return building on steady execution and solid earnings that have pushed the 1 year total shareholder return to roughly 54%, signalling momentum that still looks constructive rather than...
ENXTPA:SAN
ENXTPA:SANPharmaceuticals

Sanofi (ENXTPA:SAN) Valuation Check After Recent 2% Share Price Rebound

Sanofi (ENXTPA:SAN) shares have quietly bounced about 2% over the past week, even though they are still down for the year, drawing attention from investors looking for more resilient pharma exposure. See our latest analysis for Sanofi. That recent 7 day share price return of 2.21 percent only slightly offsets a year to date share price decline of 12.66 percent. This suggests sentiment is stabilising rather than surging, despite steady earnings growth and pipeline progress. If Sanofi has you...
ENXTPA:KER
ENXTPA:KERLuxury

Kering (ENXTPA:KER) Valuation Check After This Year’s Share Price Rebound and Recent Pullback

Kering (ENXTPA:KER) has quietly climbed this year, and with the share price hovering around €303 after a recent pullback, investors are starting to reassess whether the luxury group’s recovery has more room to run. See our latest analysis for Kering. The recent pullback sits against a strong backdrop, with a roughly 28 percent year to date share price return. This suggests sentiment toward Kering’s turnaround is improving even as the three and five year total shareholder returns remain deeply...
ENXTPA:SAN
ENXTPA:SANPharmaceuticals

Does the Market Reaction to Sanofi’s Pipeline Shift Create an Opportunity in 2025?

If you are wondering whether Sanofi is quietly turning into a bargain while everyone is focused on flashier names, this deep dive will help you assess whether the current price reflects its long term potential. Despite a solid 5 year gain of 28.1%, the stock is down 12.7% year to date and 4.6% over the last month, suggesting that sentiment has cooled even as the long term story remains intact. Recently, markets have been reacting to Sanofi's strategic shifts in its pharmaceutical pipeline...